Congenital Heart Disease — Acyanotic

Acyanotic congenital heart disease comprises structural cardiac abnormalities present at birth that do not result in right-to-left intracardiac shunting and therefore do not cause cyanosis at rest. These lesions represent the most common form of congenital heart disease, accounting for approximately 70-80% of all CHD cases, with an overall incidence of 4-10 per 1000 live births. The most frequent acyanotic lesions include atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA), and atrioventricular septal defects (AVSD), while left-sided obstructive lesions such as aortic stenosis and mitral stenosis are less common but critically important to identify. Understanding the hemodynamics, natural history, and management of acyanotic CHD is essential for clinical practice, as early diagnosis and intervention can prevent progression to heart failure, pulmonary vascular disease, and arrhythmias; furthermore, these conditions are high-yield on standardized examinations and frequently present in primary care, pediatric, and internal medicine settings.

The fundamental pathophysiologic mechanism distinguishing acyanotic from cyanotic CHD is the absence of right-to-left shunting at baseline, permitting systemic oxygen saturation to remain normal (≥95%). However, acyanotic lesions produce significant hemodynamic derangements through left-to-right shunting, volume overload, or outflow obstruction, each with distinct consequences:

Left-to-right shunts occur when structural defects (septal defects, patent vessels) permit blood to flow from the higher-pressure systemic circulation back into the lower-pressure pulmonary circulation. This increased pulmonary blood flow (Qp) relative to systemic flow (Qs)—expressed as the Qp:Qs ratio—increases workload on the left heart and pulmonary vasculature. The magnitude of shunt depends on the size of the defect and the relative resistances of the systemic and pulmonary vascular beds. Initially, the right ventricle compensates through eccentric hypertrophy, accommodating the increased volume without elevation of filling pressures. Over time, chronic volume overload leads to RV dilation, increased wall stress (LaPlace's law), and eventually contractile dysfunction. Simultaneously, the pulmonary vasculature experiences chronic exposure to elevated blood flow and pressure, triggering progressive endothelial dysfunction, muscularization of small pulmonary arterioles, and collagen deposition—a process termed pulmonary vascular remodeling. This progressive increase in pulmonary vascular resistance (PVR) follows a cascade: initially reversible with reactive pulmonary arteriolar constriction; subsequently fixed and irreversible with structural remodeling. If the defect is not corrected before PVR rises substantially, pulmonary hypertension develops, eventually reaching or exceeding systemic vascular resistance. At this critical point, the shunt reverses to become right-to-left, converting the lesion from acyanotic to cyanotic (Eisenmenger syndrome), a terminal condition with poor prognosis. The rate of PVR progression varies by lesion type (fastest with large VSDs, slower with ASDs) and is influenced by altitude, hypoxia, and genetic factors.

The combination of increased pulmonary venous return and left-to-right shunt increases preload on the left atrium and left ventricle. According to the Frank-Starling mechanism, initial increases in preload augment contractility; however, chronic excessive preload exceeds the optimal point on the Starling curve, causing chamber dilation and functional mitral regurgitation. The dilated left atrium becomes prone to atrial fibrillation and atrial arrhythmias, particularly in older patients with unrepaired ASDs. Left ventricular dilation with preserved systolic function (eccentric LV hypertrophy) eventually transitions to systolic dysfunction as afterload increases and myocardial fibrosis develops. The timing and severity of systolic dysfunction depend on the lesion size, age at correction, and presence of additional cardiac abnormalities. Pulmonary edema develops when left atrial pressure exceeds the plasma colloid osmotic pressure (~25 mmHg), leading to interstitial and alveolar edema; this manifests clinically as dyspnea, poor feeding, and failure to thrive in infants.

Left-sided obstructive lesions (aortic stenosis, mitral stenosis, coarctation of the aorta) increase afterload on the affected ventricle, triggering concentric hypertrophy—increased wall thickness relative to chamber size. This response is initially compensatory, maintaining ejection fraction and reducing wall stress; however, the hypertrophied myocardium has increased diastolic stiffness, elevated filling pressures, and impaired coronary perfusion (particularly in diastole, when subendocardial vessels are compressed). Severe or prolonged pressure overload eventually leads to systolic dysfunction, reduced compliance, and diastolic heart failure. Critical obstruction (defined variously by severity—e.g., aortic valve area <0.5 cm² in adults) can precipitate syncope, angina pectoris, or sudden cardiac death due to inadequate coronary perfusion during exertion, diminished cardiac output, or triggered arrhythmias in the setting of myocardial ischemia and fibrosis.

In certain complex lesions (e.g., some forms of tricuspid atresia not discussed in this acyanotic section, but relevant to understand spectrum), or in specific circumstances, the pulmonary or systemic circulation may become dependent on a patent ductus arteriosus or atrial septal defect for adequate blood flow. However, in isolated acyanotic lesions, this is less relevant; it becomes critical in cyanotic disease.

Turbulent blood flow through defects and abnormal valve tissue predisposes to bacterial seeding and infective endocarditis, particularly in higher-velocity jets (VSDs > ASDs). Streptococcus viridans, Staphylococcus aureus, and HACEK organisms are common causative pathogens. The risk is higher in unrepaired defects and in the presence of prosthetic material post-correction.

Acyanotic congenital heart disease arises from disruption of normal cardiac embryogenesis during the critical period of cardiac development (weeks 3-8 of gestation). The multifactorial etiology includes genetic factors, maternal environmental exposures, and chromosomal abnormalities:

Familial clustering of CHD occurs in certain populations; offspring of affected parents have a 2-10% recurrence risk depending on the specific lesion. Genetic loci associated with acyanotic CHD include mutations in GATA4, TBX5, NKX2-5, and MYH6, which encode transcription factors and contractile proteins critical for cardiac development. Autosomal dominant inheritance patterns are seen in some families (e.g., Holt-Oram syndrome with ASD and skeletal abnormalities due to TBX5 mutations). Polygenic inheritance is presumed in most sporadic cases, involving multiple susceptibility loci of modest individual effect. Copy number variations (CNVs), particularly 22q11 deletion (DiGeorge syndrome), predispose to multiple cardiac defects including ASDs and VSDs. Whole exome and genome sequencing are increasingly revealing pathogenic variants in genes not previously associated with CHD, expanding the genetic landscape.

Maternal diabetes mellitus (particularly type 1 diabetes and gestational diabetes with poor glycemic control) is a well-established risk factor, increasing the incidence of CHD 2-10 fold; the mechanism involves hyperglycemia-induced oxidative stress and altered expression of cardiac transcription factors during the critical period. Maternal infections during the first trimester—particularly rubella (associated with PDA, ASD, VSD, pulmonary stenosis, and peripheral pulmonary artery stenosis as part of congenital rubella syndrome)—increase CHD risk. Maternal alcohol consumption (fetal alcohol syndrome) is associated with ASD, VSD, and tetralogy of Fallot. Maternal medication use, including phenytoin, lithium, warfarin, ACE inhibitors, and isotretinoin (Accutane), are teratogenic; retinoic acid disrupts expression of the retinoic acid receptor and affects neural crest cell migration, critical for outflow tract development. Maternal phenylketonuria (PKU) with elevated phenylalanine levels during pregnancy increases CHD risk independent of neonatal PKU status, emphasizing the importance of maternal PKU management during pregnancy. Maternal obesity is associated with increased CHD risk. Maternal advanced age (>35 years) increases risk of chromosomal abnormalities such as trisomy 21, which is associated with AVSD and other CHD.

Trisomy 21 (Down syndrome) is associated with AVSD in approximately 40-50% of cases, as well as VSD, ASD, and tetralogy of Fallot. Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) are associated with multiple structural cardiac defects. 22q11 deletion syndrome (DiGeorge/Velocardiofacial syndrome) accounts for a significant proportion of conotruncal abnormalities and is associated with ASD, VSD, right aortic arch, and other defects. Turner syndrome (45,X) is associated with bicuspid aortic valve, coarctation of the aorta, and aortic stenosis. Williams syndrome (7q11.23 deletion) featuring elastin gene deletion is associated with supravalvular aortic stenosis and pulmonary artery stenosis. Noonan syndrome (PTPN11 and other gene mutations) presents with pulmonary stenosis and hypertrophic cardiomyopathy. Marfan syndrome (FBN1 mutation) involves fibrillin-1 defects affecting connective tissue, leading to aortic root dilation and mitral valve prolapse rather than structural CHD per se, but relevant to cardiac complications.

Beyond chromosomal abnormalities, inherited syndromes predispose to specific cardiac defects: Alagille syndrome (JAG1 mutations) associates with peripheral pulmonary artery stenosis and ASD; Ellis-van Creveld syndrome (TMEM216 mutations) with ASD and AVSD; Holt-Oram syndrome (TBX5) with ASD and VSD; Ehlers-Danlos syndrome with mitral valve prolapse and aortic dilation (Type IV); and Cornelia de Lange syndrome with VSD and ASD.

The majority of sporadic acyanotic CHD cases lack identifiable genetic mutations or environmental exposures, reflecting the polygenic, multifactorial nature of these lesions. The combination of genetic susceptibility (multiple common variants of small effect) and stochastic developmental events during critical cardiac morphogenesis likely accounts for the baseline incidence.

The clinical presentation of acyanotic congenital heart disease ranges from asymptomatic incidental findings to severe congestive heart failure and arrhythmias, depending on the specific lesion, its magnitude, age at presentation, and the presence of additional cardiac or extracardiac abnormalities. The overarching principle is that left-to-right shunts cause volume overload and pulmonary congestion, while obstructive lesions cause pressure overload and potential systemic underperfusion.

Dyspnea in acyanotic CHD results from pulmonary edema secondary to elevated left atrial pressure and increased pulmonary blood flow. In infants, dyspnea manifests as tachypnea (respiratory rate >60 breaths/min), retractions, nasal flaring, and most characteristically, poor feeding and failure to thrive. The combination of tachypnea and tachycardia (>150 beats/min) during feeding rapidly depletes caloric reserves and creates a metabolic deficit; infants with large shunts may expend 150-200% of normal resting metabolic rate. The resulting "failure to thrive" with poor weight gain despite adequate caloric intake is a hallmark presentation and often the chief complaint prompting medical evaluation. Older children may report exertional dyspnea (inability to keep up with peers during play), orthopnea, and paroxysmal nocturnal dyspnea, indicating systolic dysfunction and elevated pulmonary venous pressures.

Chronic pulmonary venous congestion and pulmonary edema impair mucociliary clearance and local immune function, predisposing to recurrent otitis media, sinusitis, pneumonia, and bronchiolitis. Infants with moderate-to-large shunts present with a history of multiple respiratory infections in the first months to years of life. This symptom complex—failure to thrive plus recurrent infections—often prompts initial pediatric evaluation and workup with chest radiography and echocardiography.

In left-sided obstructive lesions (aortic stenosis, mitral stenosis), exertional chest pain (angina pectoris) and syncope are ominous signs indicating inadequate coronary perfusion or arrhythmia in the setting of critical obstruction. The mechanism involves increased myocardial oxygen demand during exercise coupled with inability to increase cardiac output and coronary perfusion through the stenotic valve. Syncope may result from sudden hypotension, bradycardia (due to vasovagal reflex), or triggered ventricular arrhythmias in the hypertrophied, fibrotic myocardium. Sudden cardiac death can occur with critical obstruction during exertion, making these lesions high-risk and requiring urgent intervention.

Small left-to-right shunts and mild obstructive lesions may be entirely asymptomatic and discovered incidentally on routine examination or prenatal ultrasound. A systolic murmur detected during well-child examination is the most common reason for further evaluation. Some lesions (e.g., secundum ASD) may remain undetected into adulthood, presenting only when complications such as atrial fibrillation, heart failure, or pulmonary hypertension develop.

The character, timing, location, and radiation of cardiac murmurs reflect the underlying hemodynamic derangement and are critical for diagnosis. VSD produces a pansystolic (holosystolic) murmur at the left lower sternal border, loudest at the 3rd-4th intercostal space, reflecting high-velocity, continuous left-to-right shunting throughout systole; the murmur is louder with smaller, more restrictive defects (high-velocity jet) and may be soft or absent with large defects (equalization of pressures, low-velocity jet). PDA produces a continuous "machinery" murmur heard best at the left infraclavicular region and extending into diastole, reflecting continuous shunting from the aorta into the pulmonary artery throughout the cardiac cycle; this is pathognomonic when present. ASD typically produces a systolic ejection murmur at the left upper sternal border (pulmonary area), reflecting increased flow across the pulmonary valve rather than the defect itself; a diastolic rumble at the left lower sternal border may be present, reflecting increased flow across the mitral valve. Aortic stenosis produces a systolic ejection murmur at the right upper sternal border (aortic area) that radiates to the neck and may be associated with an ejection click (opening snap of the bicuspid aortic valve). Critically, the absence of a murmur does not exclude CHD; small defects, severely restricted flow, or severe ventricular dysfunction may produce inaudible murmurs.

Wide, fixed splitting of the second heart sound (S2) is characteristic of ASD and results from increased RV ejection time (due to increased RV stroke volume) and decreased LV ejection time (due to left-to-right shunt reducing LV output); importantly, the split does not vary with respiration (hence "fixed"), distinguishing it from normal physiologic splitting. Single S2 occurs with pulmonary hypertension

Endocarditis prophylaxis: per AHA, only for unrepaired cyanotic CHD, the first 6 months after prosthetic-material repair, or residual defect adjacent to prosthetic material — not routine for isolated ASD, VSD, or repaired PDA.